NASDAQ$CCRN

Cross Country Healthcare Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Cross Country Healthcare reported historic Q4 and full year financial performance driven by solid execution.

Cross Country Healthcare's Q4 2021 revenue reached $640.7 million, a 197% increase year-over-year and 71% sequentially, with net income attributable to common stockholders at $77.6 million, and adjusted EPS at $1.40.

  • Historic fourth quarter and full year financial performance due to solid execution
  • Fourth quarter financial performance exceeded all original guidance ranges
  • Year-over-year and sequential volume growth across all lines of business
  • Adjusted EBITDA margin of 12.6% for the quarter

Headline financials

Total Revenue

$641M

Previous: $216M+197.2%
EPS (adj)

$1.40

Previous: $0.19+636.8%
Capital Expenditures

$2.28M

Previous: $956K+138.5%
Free Cash Flow

-$75.6M

Previous: $973K-7874.4%
Net Income

$77.6M

Previous: $4.61M+1582.0%
Operating Income

$76M

Previous: $5.66M+1241.4%
Gross Profit

$147M

Previous: $54.4M+170.9%
Cash & Equivalents

$1.04M

Previous: $1.6M-35.3%
Total Assets

$733M

Previous: $357M+105.3%
Stock-Based Comp

$1.64M

Previous: $1.34M+22.2%

Revenue & EPS history

Cross Country Healthcare · Revenue · Quarterly

$641M

Q4 2021+197.2%vs Q4 2020
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Cross Country Healthcare · $641M total across 2 segments · Q4 2021

  • Nurse and Allied Staffing
    $620M+216.0%
  • Physician Staffing
    $20.2M+23.2%

Forward guidance

The company provided guidance for Q1 2022.

Tailwinds

  • Revenue between $740 million and $750 million
  • Adjusted EBITDA between $80.0 million and $85.0 million
  • Adjusted EPS between $1.38 and $1.48
  • Average bill rates are anticipated to remain elevated at or slightly above the fourth quarter
  • Company will continue to see volume growth throughout 2022

Headwinds

  • Gross Profit Margin between 21.5% and 22.0%
  • Adjusted EBITDA to be down 1% to up 5% sequentially
  • Adjusted EPS to be down $0.02 to up $0.08 sequentially
  • Rates will likely decline as COVID-19 hospitalizations decline
  • Does not include the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future share repurchases

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-2.7%

Avg return

Earnings day

-1.5%

Avg return

5 days after

+0.5%

Avg return

30 days after

44%

28 / 64 earnings

Positive

+24.6%

Q3 2021

Best reaction

-33.6%

Q2 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.8%+0.4%+0.8%
Q4 2025+8.2%+7.9%+0.5%
Q3 2025-14.1%-7.2%-32.9%
Q1 2025+0.4%+0.8%-6.7%
Q4 2024+0.3%-6.0%-13.9%
Q3 2024+7.2%-6.1%+57.9%
Q2 2024-2.7%-8.2%-17.3%
Q1 2024-4.9%-9.0%-14.1%
Q4 2023-2.7%-0.3%+5.7%
Q3 2023-14.0%-19.0%-10.7%
Q2 2023-14.7%-14.0%-3.8%
Q1 2023+5.1%+9.9%+26.1%
Q4 2022-5.6%+3.2%-13.2%
Q3 2022-2.5%-11.3%-2.8%
Q2 2022-13.7%-14.1%-7.6%
Q1 2022-2.6%-7.1%+0.9%
Q4 2021-1.5%+6.6%+2.4%
Q3 2021+24.6%+18.0%+21.1%
Q2 2021+23.0%+14.6%+29.7%
Q1 2021+16.5%+24.0%+17.4%
Q4 2020+18.9%+24.6%+33.8%
Q3 2020-5.0%-3.0%+9.3%
Q2 2020+9.6%+4.7%+1.6%
Q1 2020-4.8%-2.0%+7.6%
Q4 2019+0.4%-12.2%-27.7%
Q3 2019+14.2%+16.9%+10.9%
Q2 2019-0.8%-5.5%+5.6%
Q1 2019+4.7%+18.7%+0.9%
Q4 2018-3.6%-11.6%-22.5%
Q3 2018+7.8%+3.4%+2.7%
Q2 2018-30.9%-26.0%-14.7%
Q1 2018-16.7%-11.0%-4.3%
Q4 2017-18.8%-13.6%-15.8%
Q3 2017-9.6%-13.8%-2.6%
Q2 2017+3.1%+1.2%+2.5%
Q1 2017-13.0%-15.1%-16.7%
Q4 2016+3.4%-5.3%-7.2%
Q3 2016+22.9%+24.3%+31.7%
Q2 2016-11.5%-17.0%-14.2%
Q1 2016+10.0%
Q4 2015-21.9%
Q3 2015+9.5%
Q2 2015+10.1%
Q1 2015-4.6%
Q4 2014-9.6%
Q3 2014-0.5%
Q2 2014+1.8%
Q1 2014-14.3%
Q4 2013-22.3%
Q3 2013+3.1%
Q2 2013-3.3%
Q1 2013+0.4%
Q4 2009-5.5%
Q3 2012-0.9%
Q2 2012-5.5%
Q1 2011-3.1%
Q1 2012+11.8%
Q4 2011+0.8%
Q3 2010+2.5%
Q3 2011+2.5%
Q2 2011-33.6%
Q4 2010-33.6%
Q2 2010-33.6%
Q1 2010-7.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro